David H. Segal
Parkville, VIC 3052, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-XL and BCL-2.
Journal: Journal of medicinal chemistry
Published: April 27, 2021
Defining the susceptibility of colorectal cancers to BH3-mimetic compounds.
Journal: Cell death & disease
Published: May 18, 2020
Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells.
Journal: Cell death and differentiation
Published: December 08, 2019
Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells.
Journal: Cell death and differentiation
Published: March 29, 2019
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival.
Journal: Cell death & disease
Published: November 12, 2018
IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.
Journal: Blood
Published: May 11, 2018
Therapeutic Effects of a TANK-Binding Kinase 1 Inhibitor in Germinal Center-Driven Collagen-Induced Arthritis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: January 24, 2018
Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors.
Journal: ACS medicinal chemistry letters
Published: September 25, 2017
Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia.
Journal: Oncotarget
Published: May 02, 2017
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Journal: Leukemia
Published: January 29, 2017
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
Journal: Science translational medicine
Published: January 06, 2017
Last Updated: 09/26/2026